



## **Synta Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference on March 21**

March 13, 2007

LEXINGTON, Mass.--(BUSINESS WIRE)--March 13, 2007--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it will be presenting at the upcoming Lehman Brothers 10th Annual Global Healthcare Conference. Safi Bahcall, Ph.D., President and CEO, will focus on the clinical development program and novel mechanism of action of STA-4783, which has recently completed a Phase 2b clinical trial in metastatic melanoma, as well as provide a general corporate overview. The Synta presentation will begin at 11:15 a.m. (EST) on Wednesday, March 21, 2007. The conference will be held at the Loews Miami Beach Hotel in Miami.

The presentation will be available via live audio webcast on the Company's website at [www.syntapharma.com](http://www.syntapharma.com).

### About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were discovered and developed internally. For more information, please see [www.syntapharma.com](http://www.syntapharma.com).

### Safe Harbor Statement

This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in "Risk Factors" beginning on page 11 of our Registration Statement on Form S-1 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

CONTACT: Synta Pharmaceuticals Corp.  
Rob Kloppenburg, 781-541-7125  
or □  
MacDougall Biomedical Communications  
Doug MacDougall, 508-647-0209

SOURCE: Synta Pharmaceuticals Corp.